contato@gbram.org

FIQUE POR DENTRO

CIENTÍFICO

REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
01/07/2024
+leia mais
HSCT FOR MONOCLONAL GAMMOPATHIES: MULTIPLE MYELOMA AND AMYLOIDOSIS
2021
+leia mais
HSCT FOR MONOCLONAL GAMMOPATHIES: MULTIPLE MYELOMA AND AMYLOIDOSIS
03/11/2021
+leia mais
Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
Apr - Jun 2020
+leia mais
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries
6 Fev 2019
+leia mais
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
29 Ago 2018
+leia mais
Observational study of multiple myeloma in Latin America
5 Nov 2016
+leia mais
Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible
30 Out 2015
+leia mais
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
23 Jun 2012
+leia mais
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Mai 2008
+leia mais